The termination strips Nurix of all potential future milestone payments, regulatory fees, and commercial royalties tied to the specific asset. Before the announcement, Nurix shares had enjoyed a 36% climb throughout the year, closing the Tuesday session at $25.82.

Chief Executive Officer Arthur Sands downplayed the financial fallout, emphasizing that the company maintains a substantial cash runway. He noted that the firm continues to manage three other clinical-stage programs within its broader portfolio. While the SAR448272 program is defunct, Nurix remains eligible for payments from other licensed projects still active under the existing agreement with Sanofi.